Key facts
- This page summarizes Wellington Biomedical Innovation Master Investors (Cayman) I L.P.'s Form 4 filing for Boundless Bio, Inc. (BOLD).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Apr 2024, 20:42.
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - 02 Apr 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- BOLD
- Reported as of
- 02 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Apr 2024, 20:42:06 UTC
- Prior SEC filing
- 27 Mar 2024
- Next SEC filing
- 18 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- Wellington Biomedical Innovation Master Investors (Cayman) II L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Peter McIsaac, Title: Authorized Person
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. filed Form 4 for Boundless Bio, Inc. (BOLD) on 02 Apr 2024.
Change
- Previous filing in this sequence was filed on 27 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BOLD
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +189,933
- Change %
- Price
- Shares after
- 189,933
- Date
- 02 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
BOLD
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +366,300
- Change %
- +193%
- Price
- Shares after
- 556,233
- Date
- 02 Apr 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BOLD
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -3,703,704
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 189,933
- Exercise price
- Footnotes
- F1
BOLD
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -7,142,857
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 366,300
- Exercise price
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.
Footnote F2
On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date.